Clinical Trial Detail

NCT ID NCT04253964
Title Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Wake Forest University Health Sciences
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab

Carboplatin + Paclitaxel + Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.